Specific alterations of gut microbiota in diabetic microvascular complications: A systematic review and meta-analysis

• Published in: Frontiers in endocrinology (Lausanne) 2022-12, Vol.13, p.1053900-1053900
• Main Authors: Hong, Jinni, Fu, Tingting, Liu, Weizhen, Du, Yu, Min, Cunyun, Lin, Datao
• Format: Article
• Language: English
• Subjects: Bacteria; Diabetes Mellitus, Type 2 - complications; diabetic kidney disease (DKD); diabetic microvascular complication; diabetic peripheral neuropathy (DPN); diabetic retinopathy (DR); Endocrinology; Gastrointestinal Microbiome; gut microbiota (GM); Humans
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2022.1053900

The role of gut microbiota in diabetes mellitus (DM) and its complications has been widely accepted. However, the alternation of gut microbiota in diabetic microvascular complications (DC) remains to be determined. Publications (till August 20 , 2022) on gut microbiota in patients with DC were retrieved from PubMed, Web of Science, Embase and Cochrane. Review Manager 5.3 was performed to estimate the standardized mean difference (SMD) and 95% confidence interval (CI) and calculate alpha diversity indices and the relative abundance of gut microbiota between patients in DC v.s. DM and DC v.s. healthy controls (HC). We included 13 studies assessing 329 patients with DC, 232 DM patients without DC, and 241 HC. Compared to DM, patients with DC shared a significantly lower Simpson index (SMD = -0.59, 95% CI [-0.82, -0.36], p < 0.00001), but a higher ACE index (SMD = 0.42, 95% CI[0.11, 0.74], p = 0.009). Compared to HC, DC patients held a lower ACE index (SMD = -0.61, 95% CI[-1.20, -0.02], p = 0.04). The relative abundances of phylum Proteobacteria (SMD = 0.03, 95% CI[0.01, 0.04], p = 0.003, v.s. HC) and genus (SMD = 0.00, 95% CI[0.00, 0.00], p < 0.00001, v.s. HC) were enriched, accompanying with depleted abundances of phylum Firmicutes (SMD = -0.06, 95% CI[-0.11, -0.01], p = 0.02, v.s. HC), genera (SMD = -0.01, 95% CI[-0.02,-0.01], p < 0.0001, v.s. DM), (SMD = -0.01, 95% CI[-0.02, -0.00], p = 0.009, v.s. DM; SMD = -0.02, 95% CI[-0.02, -0.01], p < 0.00001, v.s. HC) and (SMD = 0.00, 95% CI[-0.00, -0.00], p < 0.00001, v.s. HC) in DC. Gut microbiota perturbations with the depletion of alpha diversity and certain short-chain fatty acids (SCFAs)-producing bacteria were associated with the pathology of DC. Therefore, gut microbiota might serve as a promising approach for the diagnosis and treatment of DC. Further investigations are required to study the mechanisms by which gut dysbiosis acts on the onset and progression of DC.